Beruflich Dokumente
Kultur Dokumente
Neurophysiology of
Optic Nerve
PREFACE
Retina
Optic nerve
Optic chiasm
Optic tract
Lateral geniculate nucleus (body)
Optic radiation ( geniculo calcarina tract )
Visual cortex
Retina
Optic Nerve
Intraocular ( 1 mm)
Intraorbital ( 25 mm)
Intracanalicular ( 5 mm )
Intra cranial ( 10 mm)
Intraocular portion
Intraorbital portion
20 mm to 30 mm long,elongated S
diameter 3-4 mm
Bermielin
Between the eyeball and the optic canal
Surrounded orbital fat,embedded the cilliary vessel
and nerve
Posteriorly,nasocilliari nerve and ophthalmic artery
cross above optic n. 25-30 mm
Surrounded anulus zinni in the orbital apex
Inflamation pain in the ocular movement
Intracanalicular potion
Intracranial portion
Optic chiasma
Optic tract
CGL
Optic radiations
Visual cortex
Blood supply
PUPILLARY PATHWAY
FUNCTION :
1.
2.
Depth of focus
The
posterior
leaf
The
anterior
leaf
dilator.
7,0 mm
in the bright adaptation:2,5 mm 6 mm.
o Miosis pupil diameter < 3 mm
o Midriasis pupil diameter > 6 mm
o size
They
Parasymphatetic
pathway
Sympathetic
pathway
cavernous sinus
Synapse
superior orbital
fissura
ciliary muscles
Ciliary ganglion
sphincter muscles
PUPIL EXAMINATION
1.
2.
3.
4.
5.
6.
7.
Parasymphatetic defect :
1. Adies (tonic) pupil
2. Midriasis
Symphatetic defect :
1. Horner s syndrome
2. Argyll Robertson Pupil
1. Papil Atrophy
-
primary
- secondary
2. Neuritis Optik:
- Typical
- Atypical
- Neuroretinitis
3.
4.
5.
6.
7.
Neuroretinitis
Non arteritis AION
Arteritik AION
Posterior Ischaemic optic
neuropathy
Diabetic papillopathy
Classification of etiology:
Vascular
Degenerative
Secondary due to papillodema
Secondary due to optic neuritis
Optic compressive
Toxic
Matabolic
Traumatic
Glaucoma
Clinical finding:
- visual field loss, reduced of colour
vision
- pale optic disc
- Pupil reaction comparable with
decrease of visual acuity
Optic Atrophy
neuritis
Compression of tumor or aneurysm
Hereditary optic neuropathy
Toxic optic neuropathy
papilitis, AION
Age 30-50,
Subacute monocular visual
impairment
Discomfort surounding eye with
movement
Normal papil optic nerve
temporal pale recurrent attact
VA worsen in few days 2 weeks,
improvement with in 2-4 weeks.
Relationship with MS
Neuroretinitis
age >50 th
Due to ischaemic process
Painless monocular visual loss
Visual field deffect : altitudinal or
arcuate
Divided into Arteritic AION and Non
Arteritic AION
Diabetic papillopathy
type 1 dan 2 DM
Blurred vision, painless
RAPD +/VF defect : enlargement of blind spot
Papilledema, hyperemia, and surface
telangiectasis.
scotoma
Characterized : gradual,
progressive, bilateral and painless
Central or cecocentral scotoma
Decrease of visual acuity and colour
vision
Mild to moderate papil edema
Cause : > methanol
medication : INH,
ethambutol
INTRODUCTION
CHALLENGES
ETHANOL
ethyl alcohol, drinking alcohol,
grain alcohol
Very rare,Chronis, Liver dissorder,
Malnutrition
Fermentation alcohol low
concentration
Distilation alcohol high concentration
METHANOL
methyl alcohol, wood
alcohol, wood naphta or wood
spirits
CHEAP, SWEET
Formic acid Neurotoxin Optic nerve
damage
Serum levels 20 mg/dL ocular
injury
PATOPHYSIOLOGY
Methanol
Methanol
Alcohol dehydrogenase
Formaldehyde
Formaldehyde
Formaldehyde dehydrogenase
Formic acid
Formic acid
Mitochondrial RGC disruption
Mitochondrial RGC disruption
ROS
ROS
Cytochrom C
Cytochrom C
release
release
Caspase 2, 9activation
Caspase 2, 9activation
Caspase 3
Caspase 3
activation
activation
Apoptosis
SGR
Apoptosis SGR
11/6/16
Visual acuity
Visual acuity
Caspase 8
Caspase 8
activation
activation
ATP
ATP
GSH
GSH
Death receptor
Death receptor
89
symptoms
91
signs
92
Management
MANAGEMENT
93
MANAGEMENT
SUPPLEMENTATION
SUPPLEMENTATION
Folic
acid
Folic acid
Vitamin
VitaminBB
Adenosin
AdenosinTri
TriPhosphat
Phosphat(ATP)
(ATP)
Steroid
Steroid
94
95
Folic acid
Compensation of deficiency Hepatic H4 folat
to counter / enhance the metabolism of
formate side effect <<
acute : 4 x 1 mg/kgbw ( max 50 mg) oral 3
x 1 tablet
Mitochondrial protector
Ubiquinone, L-carnitine, Co enzyme Q 10
Gingko biloba
96
Morbidity
97
Prognosis
Variable
Depends upon the nature of the
agent, total exposure prior to
removal
Degree of vision loss at the time of
diagnosis.
98
Neuroimaging
99
INTRODUCTION
Tuberculosis caused by
mycobacterium tuberculosis.
ETHAMBUTOL
Structure of ethambutol
dihydrochloride
PATHOGENESIS
...Pathogenesis
CLINICAL PRESENTATION
Decreased Vision.
bilateral progressive painless visual
blurring ( minimal reduction
NLP ).
Onset ocular symptoms 2 - 5
months
Pupil response
Bilaterally sluggish to light with no
RAPD.
Optic nerve
fundoscopic is usually normal, but
showed swelling and hyperemia
follow with splinter haemorhage
later.
ADDITIONAL EXAMINATION
Dose-related
Incidence of ethambutol related
retrobulbar neuritis of
18% >35mg/kg/day
5-6% 25mg/kg/day
<1% 15mg/kg/day
in patient receiving ethambutol for
more than two months.
b. Duration-related
Manifestation of ocular toxicity is
usually delayed, which generally
doesnt develop until after
treatment for at least 1,5
months.
Variable mean interval between
onset of therapy and toxic effect
3 5 months
c. Reversibility
Classically described as reversible on
discontinuation of ethambutol ( weeks
to months ).
Studies have reported permanent
visual impairment without recovery in
some patients with prompt
ethambutol discontinuation.
DIAGNOSIS
1.
2.
3.
4.
5.
Receiving treatment of
ethambutol.
Decreased visual acuity
Earliest sign of dyscrhomatopsia
Optic disc : normal/swelling/pallor
Visual field defect :
central/secocentral, bilateral
hemianopsia, perifer contriction
MANAGEMENT
PREVENTIVE
a. Patient should be assessed for:
- Feasibility and contraindication of
using ethambutol.
b. Patient with difficulty in appreciating
and reporting visual symptoms or
change of vision like young children,
person with language difficulties
contraindicated
c.
d.
Health education
Baseline vision test
visual acuity and colour perception
should be conducted before starting
treatment.
Especially high dosage
>25mg/kg/day
PROGNOSIS
SCREENING
Frequency of examination is
monthly
- Doses 15mg/kg/day .
- Patients at increased risk for
toxicity:
DM, Chronic renal failure,
alcoholism,eldrerly, children, other
ocular defects, induced periperal
neuropathy.
SCREENING
PAPILLOEDEMA
Mechanisme of papilloedema
2.
Etiology of Papilloedema
Cerebral Tumors
Abcess
Subdural hematome
Acquired hydrocephalus
Arteriovenous malformation
Malignan hypertension
Spinal tumor
Uremia
mucopolisacharidosis
Ophthalmoscopic finding
Optic disc edema :
>3D
non delineated
margin, Spot
haemorrhage
turtous vein
Chiasm lesions
Etiology
1. Tumor
3. others:
Chiasm lesion
Ussually compresive
Pediatric
Hypothalamic
glioma
Craniopharyngioma
Adult
Pituitary
adenoma
Meningioma
Craniopharyngioma
Aneurysm
Retrochiasmal lesion
Retrochiasmal Lesions
Optic tract
1. Incongruous homonimous
hemianopia
2. Wernicke hemianopic pupil
3. Optic atrophy
4. Contralateral pyramidal sign
inferior
Main Radiation
1.VF defect : complete
homonimous hemianopia
2.Optokinetic nystagmus
Striate cortex
1. VF defect : Macular sparing
congruous homonimous hemianopia
2. Associated feature : visual
hallucination, denial of blindness
3. causes : vascular disease,
migraine, tumor and trauma.
LAPANG PANDANG
Dinilai menggunakan :
PERIMETERI :
- Statik ( Humprey )
- Kinetik ( Goldman )
Untuk diagnostik dan evaluasi terapi
Dokter Umum Konfrontasi
LP normal dg Goldmann
THANK YOU
THANK U